Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies - PubMed (original) (raw)
Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies
M Kelliher et al. Neuroscience. 1999.
Abstract
Investigation of the integrity of the ryanodine receptor in Alzheimer's disease is important because it plays a critical role in the regulation of calcium release from the endoplasmic reticulum in brain, impairment of which is believed to contribute to the pathogenesis of Alzheimer's disease. The present study compared ryanodine receptor levels and their functional modulation in particulate fractions from control and Alzheimer's disease temporal cortex, occipital cortex and putamen. Relationships between ryanodine receptor changes and the progression of Alzheimer's disease pathology were determined by examining autoradiographic [3H]ryanodine binding in entorhinal cortex/anterior hippocampus sections from 22 cases that had been staged for neurofibrillary changes and beta-amyloid deposition. A significant (P < 0.02) 40% decrease in the Bmax for [3H]ryanodine binding and significantly higher IC50 values for both magnesium and Ruthenium Red inhibition of [3H]ryanodine binding were detected in Alzheimer's disease temporal cortex particulate fractions compared to controls. Immunoblot analyses showed Type 2 ryanodine receptor holoprotein levels to be decreased by 20% (P < 0.05) in these Alzheimer's disease cases compared to controls. No significant differences were detected in [3H]ryanodine binding comparing control and Alzheimer's disease occipital cortex or putamen samples. The autoradiography study detected increased [3H]ryanodine binding in the subiculum, CA2 and CA1 regions in cases with early (stage I-II) neurofibrillary pathology when compared to Stage 0 cases. Analysis of variance of data with respect to the different stages of neurofibrillary pathology revealed significant stage-related declines of [3H]ryanodine binding in the subiculum (P < 0.02) with trends towards significant decreases in CA1, CA2 and CA4. Post-hoc testing with Fisher's PLSD showed significant reductions (74-94%) of [3H]ryanodine binding in the subiculum, and CA1-CA4 regions of the late isocortical stage (V-VI) cases compared to the early entorhinal stage I-II cases. [3H]Ryanodine binding also showed significant declines with staging for beta-amyloid deposition in the entorhinal cortex (P < 0.01) and CA4 (P < 0.05) with trends towards a significant decrease in the dentate gyrus. We conclude that alterations in ryanodine receptor binding and function are very early events in the pathogenesis of Alzheimer's disease, and may be fundamental to the progression of both neurofibrillary and beta-amyloid pathologies.
Similar articles
- Loss of inositol 1,4,5-trisphosphate receptor sites and decreased PKC levels correlate with staging of Alzheimer's disease neurofibrillary pathology.
Kurumatani T, Fastbom J, Bonkale WL, Bogdanovic N, Winblad B, Ohm TG, Cowburn RF. Kurumatani T, et al. Brain Res. 1998 Jun 15;796(1-2):209-21. doi: 10.1016/s0006-8993(98)00347-3. Brain Res. 1998. PMID: 9689471 - Quantitative autoradiography of [3H]forskolin binding sites in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits.
García-Jiménez A, Cowburn RF, Ohm TG, Bogdanovic N, Winblad B, Fastbom J. García-Jiménez A, et al. Brain Res. 1999 Dec 11;850(1-2):104-17. doi: 10.1016/s0006-8993(99)02111-3. Brain Res. 1999. PMID: 10629754 - Evolution of the neuropathology of Alzheimer's disease.
Braak H, Braak E. Braak H, et al. Acta Neurol Scand Suppl. 1996;165:3-12. doi: 10.1111/j.1600-0404.1996.tb05866.x. Acta Neurol Scand Suppl. 1996. PMID: 8740983 Review. - Amyloid-beta, tau, and dementia.
Takashima A. Takashima A. J Alzheimers Dis. 2009;17(4):729-36. doi: 10.3233/JAD-2009-1090. J Alzheimers Dis. 2009. PMID: 19542626 Review.
Cited by
- A Gating Mutation in Ryanodine Receptor Type 2 Rescues Phenotypes of Alzheimer's Disease Mouse Models by Upregulating Neuronal Autophagy.
Zhang H, Knight C, Chen SRW, Bezprozvanny I. Zhang H, et al. J Neurosci. 2023 Feb 22;43(8):1441-1454. doi: 10.1523/JNEUROSCI.1820-22.2022. Epub 2023 Jan 10. J Neurosci. 2023. PMID: 36627208 Free PMC article. - Identification of Cerebral Metal Ion Imbalance in the Brain of Aging Octodon degus.
Braidy N, Poljak A, Marjo C, Rutlidge H, Rich A, Jugder BE, Jayasena T, Inestrosa NC, Sachdev PS. Braidy N, et al. Front Aging Neurosci. 2017 Mar 29;9:66. doi: 10.3389/fnagi.2017.00066. eCollection 2017. Front Aging Neurosci. 2017. PMID: 28405187 Free PMC article. - The synthetic TRPML1 agonist ML-SA1 rescues Alzheimer-related alterations of the endosomal-autophagic-lysosomal system.
Somogyi A, Kirkham ED, Lloyd-Evans E, Winston J, Allen ND, Mackrill JJ, Anderson KE, Hawkins PT, Gardiner SE, Waller-Evans H, Sims R, Boland B, O'Neill C. Somogyi A, et al. J Cell Sci. 2023 Mar 15;136(6):jcs259875. doi: 10.1242/jcs.259875. Epub 2023 Mar 21. J Cell Sci. 2023. PMID: 36825945 Free PMC article. - Repurposing Licensed Drugs for Use Against Alzheimer's Disease.
Norins LC. Norins LC. J Alzheimers Dis. 2021;81(3):921-932. doi: 10.3233/JAD-210080. J Alzheimers Dis. 2021. PMID: 33843684 Free PMC article. Review. - Hippocampal Subregion and Gene Detection in Alzheimer's Disease Based on Genetic Clustering Random Forest.
Li J, Liu W, Cao L, Luo H, Xu S, Bao P, Meng X, Liang H, Fang S. Li J, et al. Genes (Basel). 2021 May 1;12(5):683. doi: 10.3390/genes12050683. Genes (Basel). 2021. PMID: 34062866 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous